PHARMACOLOGICAL ACTIVATION OF THE p53 PATHWAY BY NUTLIN-3 EXERTS ANTI-TUMORAL EFFECTS IN MEDULLOBLASTOMAS

被引：0
|
作者：
Kuenkele, Annette [1 ]
De Preter, Katleen [2 ]
Heukamp, Lukas [3 ]
Thor, Theresa [1 ]
Pajtler, Kristian [1 ]
Hartmann, Wolfgang [3 ]
Mittelbronn, Michel [4 ]
Grotzer, Michael [5 ]
Deubzer, Hedwig [6 ]
Speleman, Frank [2 ]
Schramm, Alexander [1 ]
Eggert, Angelika [1 ]
Schulte, Johannes [1 ]
机构：
[1] Univ Childrens Hosp Essen, Essen, Germany
[2] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium
[3] Univ Hosp Cologne, Inst Pathol, Cologne, Germany
[4] Goethe Univ Frankfurt, Inst Neurol, Frankfurt, Germany
[5] Childrens Hosp Zurich, Zurich, Switzerland
[6] German Canc Res Ctr, D-6900 Heidelberg, Germany
来源：
NEURO-ONCOLOGY | 2012年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [31] Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
    McCormack, E.
    Haaland, I.
    Venas, G.
    Forthun, R. B.
    Huseby, S.
    Gausdal, G.
    Knappskog, S.
    Micklem, D. R.
    Lorens, J. B.
    Bruserud, O.
    Gjertsen, B. T.
    LEUKEMIA, 2012, 26 (05) : 910 - 917
  • [32] Activation of the p53 pathway by the MDM2 antagonist nutlin-3 downregulates the DNA repair protein hABH2 and sensitizes glioma cells to chemotherapy
    Johannessen, Tor-Christian A.
    Prestegarden, Lars
    Grudic, Amra
    Tysnes, Bent B.
    Bjerkvig, Rolf
    CANCER RESEARCH, 2011, 71
  • [33] Natural and synthetic inhibitors of mTOR blunt the p53 response to low concentrations of actinomycin D but not nutlin-3
    Goudarzi, K. M.
    Nister, M.
    Lindstrom, M. S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S72 - S72
  • [34] Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma
    Tongsen Zheng
    Dalong Yin
    Zhaoyang Lu
    Jiabei Wang
    Yuejin Li
    Xi Chen
    Yingjian Liang
    Xuan Song
    Shuyi Qi
    Boshi Sun
    Changming Xie
    Xianzhi Meng
    Shangha Pan
    Jiaren Liu
    Hongchi Jiang
    Lianxin Liu
    Molecular Cancer, 13
  • [35] p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
    Chappell, William H.
    Lehmann, Brian D.
    Terrian, David M.
    Abrams, Stephen L.
    Steelman, Linda S.
    McCubrey, James A.
    CELL CYCLE, 2012, 11 (24) : 4579 - 4588
  • [36] Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy
    Pishas, Kathleen I.
    Neuhaus, Susan J.
    Clayer, Mark T.
    Adwal, Alaknanda
    Brown, Michael P.
    Evdokiou, Andreas
    Callen, David F.
    Neilsen, Paul M.
    ONCOLOGY REPORTS, 2013, 30 (01) : 471 - 477
  • [37] Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation
    Mochizuki, Hiroyuki
    Goto-Koshino, Yuko
    Sato, Masahiko
    Fujino, Yasuhito
    Ohno, Koichi
    Tsujimoto, Hajime
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2012, 147 (3-4) : 187 - 194
  • [38] Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells
    Shi, Xinli
    Liu, Jingli
    Ren, Laifeng
    Mao, Nan
    Tan, Fang
    Ding, Nana
    Yang, Jing
    Li, Mingyuan
    BMB REPORTS, 2014, 47 (04) : 221 - 226
  • [39] The MDM2 antagonist nutlin-3 is lethal to mantle cell lymphoma with wild type p53
    Tabe, Yoko
    Szbasigari, Denise
    Rudelius, Martina
    Pittaluga, Stefania
    Raffel, Mark
    BLOOD, 2007, 110 (11) : 415A - 415A
  • [40] Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph plus ALL
    Guo, Yong
    Li, Yi
    Xiang, Bing
    Huang, Xiao-Ou
    Ma, Hong-Bing
    Wang, Fang-Fang
    Gong, Yu-Ping
    BIOCHEMICAL JOURNAL, 2017, 474 : 4153 - 4170
12345